Pune-based Gennova to start phase I human trials with 120 volunteers in two hospitals

Gennova Biopharmaceutical’s vaccine candidate is the first mRNA-based vaccine to be produced in India. (Representative Image, IE) After Covaxin and Covishield, now Pune-based drugmaker firm, Gennova Biopharmaceuticals is all set to start early to mid-stage human trials of its Covid-19 vaccine, HGCO19. The trials will start ‘’soon’’ and around 620 people will be enrolled for the vaccination…

HGCO19 Gennova Vaccine: India’s first indigenous mRNA COVID-19 vaccine candidate gets nod for human trial

The mRNA vaccines do not use the conventional model to produce immune response India’s first indigenous mRNA vaccine candidate has received approval from the drug regulators to start Phase I/II human clinical trial. The novel mRNA vaccine candidate, HGCO19 has been developed by Gennova, Pune and supported with seed grant under the Ind-CEPI mission of Department of Biotechnology of M/o Science &…

Gennova Bio gets US drug patent to treat brain clots

[ad_1]

MUMBAI: Decks have been cleared for a more affordable stroke treatment — developed by domestic company Gennova Biopharmaceuticals — to go global. The Pune-based biotech company has been granted a patent in the US for its version of drug tenecteplase, to treat brain clots (ischemic stroke), the first ever in the world. Till now, drug alteplasehas been largely considered the gold standard…